Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers

PET Clin. 2017 Oct;12(4):393-405. doi: 10.1016/j.cpet.2017.05.007. Epub 2017 Jul 19.

Abstract

Gynecologic cancer is a heterogeneous group of diseases both functionally and morphologically. Today, PET coupled with computed tomography (PET/CT) or PET/MR imaging play a central role in the precision medicine algorithm of patients with gynecologic malignancy. In particular, PET/CT and PET/MR imaging are molecular imaging techniques that not only are useful tools for initial staging and restaging but provide anatomofunctional insight and can serve as predictive and prognostic biomarkers of response in patients with gynecologic malignancy.

Keywords: Cancer staging; Cervical cancer; Endometrial cancer; Gynecologic malignancy; Ovarian cancer; Positron emission tomography; Precision medicine; Uterine cancer.

Publication types

  • Review

MeSH terms

  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Magnetic Resonance Imaging, Interventional
  • Molecular Imaging / methods*
  • Neoplasm Staging
  • Ovarian Neoplasms / diagnostic imaging*
  • Ovarian Neoplasms / therapy
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography / methods*
  • Precision Medicine / methods*
  • Radiopharmaceuticals
  • Tomography, X-Ray Computed
  • Uterine Neoplasms / diagnostic imaging*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18